3 results - showing 1 - 3
Ordering
Details
Ratings
Journal Watch
ICNA
ICNA
May 26, 2019 1412 0
Lancet 2019
Background Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus.
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
ICNA
ICNA
Updated June 11, 2018 1980 0
The Lancet May 23, 2018
Paolo Curatolo, David N Franz, John A Lawson, Zuhal Yapici, Hiroko Ikeda, Tilman Polster, Rima Nabbout, Petrus J de Vries, Dennis J Dlugos, Jenna Fan, Antonia Ridolfi, Diana Pelov, Maurizio Voi, Jacqueline A French https://doi.org/10.1016/S2352-4642(18)30099-3 Background Epilepsy occurs in 70–90% of patients with tuberous sclerosis complex. We aimed to assess the efficacy and safety of adjunctive everolimus for treatment-refractory seizures associated with tuberous sclerosis complex in paediatric patients enrolled in the EXIST-3 trial, a double-blind, placebo-controlled, randomised, phase 3 study. Methods This post-hoc analysis focused on paediatric patients...
Read more Write review
 
0.0
 
0.0 (0)
Journal Watch
ICNA
ICNA
Updated July 27, 2017 3750 1
Lancet. 2017 Jul 17
Background Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein production are being explored. We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD.
Read more Write review
 
0.0
 
0.0 (0)
3 results - showing 1 - 3